Biomarker Panel Predicts Immunotherapy Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the effectiveness of immunotherapy in cancer patients lack reliable biological markers, making it difficult to determine the prognosis and outcome of treatment, particularly for renal cell carcinoma (RCC) and colorectal carcinoma (CRC).
Innovation Solution
A method using a panel of biomarkers such as ApoA1, CCL17/TARC, CXCL13/BCA-1, neutrophils, eosinophils, monocytes, CD95/Fas, ASAT/SGOT, and others to predict the beneficial effect of immunotherapy, including peptide-based vaccines, and monitor treatment response in cancer patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current prediction methods are used, then treatment can proceed, but reliability of prediction is insufficient
Solution Approach 1:
The patent segments the prediction system into multiple independent biomarker components (ApoA1, CCL17/TARC, CXCL13/BCA-1, and cellular parameters) that can be measured separately and combined to form a comprehensive prediction model, thereby improving reliability through multi-factor analysis
Solution Approach 2:
The patent develops a universal prediction method that can be applied across different cancer types (renal cell carcinoma, colorectal carcinoma, and other solid tumors) using the same panel of biomarkers, making the solution broadly applicable and reliable for diverse clinical scenarios
2Measurement precision
If a panel of biomarkers is used, then prediction accuracy improves, but device complexity increases
Solution Approach 1:
The complex prediction task is segmented into measurements of distinct, well-defined biomarkers (ApoA1, CCL17/TARC, CXCL13/BCA-1, neutrophils, eosinophils, monocytes, CD95/Fas, ASAT/SGOT) that can be processed independently and then integrated, making the complexity manageable through modular measurement approaches
Solution Approach 2:
The patent introduces a standardized biomarker panel as an intermediary layer between the patient sample and the clinical decision-making process, translating complex biological information into interpretable prediction results through defined measurement protocols and reference ranges
3Productivity
If immunotherapy is administered without reliable prediction, then treatment access is improved, but loss of time due to ineffective treatment increases
Solution Approach 1:
The patent performs preliminary prediction using the biomarker panel before initiating immunotherapy, identifying patients likely to respond favorably in advance, thereby preventing time loss from ineffective treatments while maintaining access for those who will benefit
Solution Approach 2:
The patent establishes a feedback mechanism where biomarker measurements inform treatment decisions, creating a closed-loop system that directs immunotherapy to responsive patients and alternative treatments to non-responders, optimizing time utilization across the patient population
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 2A~2C
AI summary
The present invention relates to methods for predicting the effect of an immunotherapy against cancer in a patient based on new biomarkers. The present invention furthermore relates to a prognosis regarding the outcome based on said biomarkers. The present invention furthermore relates to panels of biomarkers for use in the above methods.